Cellebrite DI Ltd. (CLBT)
Cellebrite DI Eyes AI, Cloud and FedRAMP as Digital Investigations Demand Grows
Cellebrite DI NASDAQ: CLBT executives said the company is seeing broader customer adoption of its digital investigations platform, with artificial intelligence, cloud migration and U.S. federal authorization expected to shape its next phase of growth.
Cellebrite DI Sees Federal Rebound as AI, Defense Tools Fuel New Growth
Cellebrite DI NASDAQ: CLBT executives said the digital investigations company is seeing renewed momentum in government demand, international markets and new product categories, including artificial intelligence and defense-focused capabilities, during a JPMorgan cybersecurity and DevOps event hosted by analyst Brian Essex.
Cellebrite DI Ltd. (CLBT) Presents at J.P.
Cellebrite DI Ltd. (CLBT) Presents at J.P.
Cellebrite: Positive Q1 Results, But There Is Room For Margin Improvements
Cellebrite delivered strong Q1 2026 results, with 19% revenue growth and notable subscription and ARR gains, beating analyst expectations. CLBT expanded its portfolio with the SCG Canada acquisition and launched AI-powered solutions, positioning itself for long-term growth and broader market reach. Despite robust top-line growth, gross, operating, and net margins declined; margin expansion remains a key area to monitor.
Cellebrite DI Q1 Earnings Call Highlights
Cellebrite DI NASDAQ: CLBT reported first-quarter 2026 results that management said met or exceeded the high end of its guidance for annual recurring revenue and adjusted EBITDA, while executives highlighted a wave of new product launches centered on artificial intelligence, cloud-based case management and mobile device access.
Cellebrite DI Ltd. (CLBT) Q1 Earnings and Revenues Top Estimates
Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.11 per share.
Cellebrite: A Rare SaaS Play Where AI Is A Tailwind, Not A Threat
Cellebrite DI operates in a niche with strong regulatory moats, high switching costs, and robust customer entrenchment. CLBT's financials are solid: subscription revenue up 21%, ARR at $481M, Rule of 40 above 55, and FCF margin at 34%. AI integration enhances CLBT's value proposition, accelerating evidence discovery and reinforcing its competitive positioning and growth prospects.
Cellebrite DI Ltd. (CLBT) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Cellebrite DI Ltd. (CLBT) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Cellebrite DI Ltd. (CLBT) Q4 2025 Earnings Call Transcript
Cellebrite DI Ltd. (CLBT) Q4 2025 Earnings Call Transcript
Cellebrite DI Ltd. (CLBT) Matches Q4 Earnings Estimates
Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.14 per share, in line with the Zacks Consensus Estimate.
Cellebrite DI Ltd. (CLBT) Presents at UBS Global Technology and AI Conference 2025 Transcript
Cellebrite DI Ltd. (CLBT) Presents at UBS Global Technology and AI Conference 2025 Transcript
Cellebrite DI: Strong Q3, But Valuation And Technical Issues Could Weigh On The Stock (Rating Downgrade)
Cellebrite DI remains a long-term growth story, despite recent volatility and a modest stock decline since November 2024. CLBT's Q3 2025 earnings beat analyst expectations, with revenue up 18% year-over-year to $126 million and EPS of $0.14. Valuation and technical concerns persist, which could lead to further selling or an underperformance for the stock.
